Invivyd (IVVD) Q2 2024 earnings summary

Executive summary

• Commercial launch of PEMGARDA in Q2 2024 generated $2.3 million in revenue, with rapid acceleration in commercial momentum and expanded infusion center utilization into early Q3.

• Leadership transition and addition of new executives and directors aimed at strengthening operations and commercial execution.

• EUA granted for PEMGARDA in March 2024 for pre-exposure prophylaxis in immunocompromised individuals; EUA amendment submitted in July 2024 for treatment of mild-to-moderate COVID-19.

• Pipeline advancing with VYD2311 entering first-in-human clinical trials in late August and CANOPY 180-day data submitted to FDA.

• Ongoing focus on R&D for COVID-19 and other viral diseases, with partnerships and internal discovery efforts.

Financial highlights

• Q2 2024 product revenue was $2.3 million, with cash and cash equivalents of $147.9 million as of June 30, 2024.

• Net loss for Q2 2024 was $47.2 million ($0.40 per share), an improvement from $50.2 million ($0.46 per share) in Q2 2023.

• R&D expenses decreased to $30.3 million in Q2 2024, mainly due to lower PEMGARDA manufacturing costs.

• SG&A expenses rose to $21.1 million in Q2 2024, reflecting increased commercialization costs.

• Revenue guidance for 2024 reiterated at $150–$200 million, with year-end cash projected at $75 million.

Outlook and guidance

• Expects to end 2024 with at least $75 million in cash and maintain 2024 revenue guidance of $150–$200 million.

• Anticipates a major commercial moment in fall 2024, with peak demand for respiratory virus protection in September–November.

• Fall activation plan includes digital campaigns, expanded sales force, and increased access to infusion sites.

• Current cash resources are not sufficient to fund operations beyond one year without additional revenue or external financing, raising substantial doubt about the ability to continue as a going concern.

• Additional funding will be sought through equity offerings, grants, debt, or strategic partnerships.